Journal of Diabetes and Metabolic Disorders最新文献

{"title":"Association of periodontitis with lipid profile: an updated systematic review and meta-analysis.","authors":"Ahmadreza Mirzaei,&nbsp;Ehsan Shahrestanaki,&nbsp;Hanieh Malmir,&nbsp;Hanieh-Sadat Ejtahed,&nbsp;Doreen Tajbakhsh,&nbsp;Ehsan Seif,&nbsp;Shirin Djalalinia,&nbsp;Armita Mahdavi-Gorabi,&nbsp;Mostafa Qorbani","doi":"10.1007/s40200-022-01071-7","DOIUrl":"https://doi.org/10.1007/s40200-022-01071-7","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this updated version of the systematic review and meta-analysis was to assess the association of PD with lipid profile.</p><p><strong>Methods: </strong>A comprehensive literature search was done in electronic databases including PubMed, Web of Science, and Scopus until August 2021. Cross-sectional, case-control, and cohort studies investigating the relationship between PD and lipid profile were included. Screening, data extraction, and quality assessment were performed independently by two investigators. A random-effect model was used to pool the effect size. Odds ratio (OR) was used as effect size for the association of PD with Hyperlipidemia, and SMD was used for the association of PD with the mean level of lipid profile.</p><p><strong>Results: </strong>Overall, 34 documents met the inclusion criteria for this systematic review, and 31 were included for the meta-analysis. Sixteen studies were cross-sectional, 16 case-control, and two cohorts. Results of the random effect model showed that PD increased the odds of dyslipidemia by 15% (OR: 1.15, 95% CI: 1.04, 1.26). The Association of PD with low HDL, high LDL, hypertriglyceridemia, and hypercholesteremia was not statistically significant (P > 0.05). The mean level of HDL in patients with PD was significantly lower than in subjects without PD (SMD: -0.69, 95% CI: -1.11, -0.26). Moreover, the mean level of LDL, TC, TG in patients with PD was significantly higher than in subjects without PD (P < 0.05).</p><p><strong>Conclusions: </strong>This meta-analysis suggests that periodontitis is associated with an increased odds of dyslipidemia. Therefore, treating periodontitis may improve dyslipidemia, particularly HDL and triglyceride levels.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672167/pdf/40200_2022_Article_1071.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9695251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and reasons influenced medication non-adherence among diabetes patients: A mixed-method study.","authors":"Nor Fadhilah Abdullah,&nbsp;Lee Khuan,&nbsp;Cheong Ai Theng,&nbsp;Siti Noorkhairina Sowtali","doi":"10.1007/s40200-022-01118-9","DOIUrl":"https://doi.org/10.1007/s40200-022-01118-9","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to identify the prevalence of medication non-adherence (MNA) and to explore the reasons that influenced MNA among diabetes patients.</p><p><strong>Design: </strong>This study used the explanatory mixed-method design. Phase one comprised of a cross-sectional study followed by phase two of a qualitative study.</p><p><strong>Setting: </strong>This study took place at two public hospitals in the Klang Valley, Malaysia.</p><p><strong>Participants: </strong>About 427 diabetes patients were recruited and 399 of them completed the study. The inclusion criteria were those with age more than 18 years and above, Malaysian citizen, able to understand Malay or English, and were diagnosed with diabetes mellitus for more than one year. The exclusion criteria were those with an intellectual disability and pregnant women. Phase two involved 12 participants recruited from non-adherent patients in phase one of the study.</p><p><strong>Results: </strong>About 46.6% of the patients failed to adhere to the medication. Malays (OR: 1.66, 95%CI: 1.09 to 2.51, <i>p</i> = 0.017), single/widow or divorced (OR: 1.79, 95%CI: 1.05 to 3.05, <i>p</i> = 0.031) and poor HbA1c (OR: 2.57, 95% CI: 1.61 to 4.10, <i>p</i> =  < 0.01) were associated with medication non-adherence. Five main categories emerged as the reasons for medication non-adherence, including perceived benefit of Complementary and Alternative medicine, attitude towards drawback of western medication, poor healthcare providers and patients' relationship, undesirable emotional response towards medication intake, as well as restraints in daily routine and cognitive function.</p><p><strong>Conclusions: </strong>There are many reasons for patients' non-adherence to their anti-diabetes medication. These findings are important in identifying the factors that influenced non-adherence to recommend reliable patient-centred care strategies in improving medication non-adherence among patients with diabetes.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672180/pdf/40200_2022_Article_1118.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10226021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of <i>Costus pictus per se</i> and in combination with Metformin and Enalapril in streptozotocin induced diabetic nephropathy in rats.","authors":"Mrinal Sanaye,&nbsp;Greeshma Sathyapal,&nbsp;Yogesh A Kulkarni","doi":"10.1007/s40200-022-01065-5","DOIUrl":"https://doi.org/10.1007/s40200-022-01065-5","url":null,"abstract":"<p><strong>Aim: </strong>The present study was designed to investigate the effect of methanolic extract of <i>Costus pictus</i> (MECP) <i>per se</i> and in combination with drugs (Metformin and Enalapril) used in clinical practice in streptozotocin (STZ) induced diabetic nephropathy (DN) in rats.</p><p><strong>Methods: </strong>Diabetes was induced in male Wistar rats by a single injection of STZ (50 mg/kg <i>i.p.</i>). After 28 days diabetic rats were divided into six groups. Two groups were treated with MECP (200 mg/kg <i>p.o</i>.), MECP (400 mg/kg <i>p.o</i>.) respectively; one group was treated with metformin (225 mg/kg), enalapril (3.2 mg/kg) combination; and two groups were treated with a combination of metformin, enalapril and MECP (200 mg/kg) and combination of metformin, enalapril and MECP (400 mg/kg) respectively. One group was kept as diabetic control. At the end of the study, body weight, kidney weight, and kidney hypertrophy index were evaluated. Biochemical and antioxidant parameters were evaluated. TGF-β levels in serum were estimated. Histopathology of the kidney was also studied.</p><p><strong>Results: </strong>The combination therapy showed a significant increase in the body weight, lowered blood glucose levels and ameliorated kidney hypertrophy index in STZ induced diabetic nephropathy in rats. It also normalized the altered levels of serum and urine parameters. Histopathological evaluation revealed that combination therapy reduced the vacuolar degeneration of tubules.</p><p><strong>Conclusions: </strong>The results indicate that combination therapy of metformin, enalapril, and MECP has beneficial effects in management of diabetic nephropathy.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672202/pdf/40200_2022_Article_1065.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9819863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study Protocol titled as \"Effectiveness of neural mobilization in improving the ankle ROM and plantar pressure distribution in patients with diabetic peripheral neuropathy: A single group, pre post, quasi experimental study protocol\".","authors":"Madhu Goyat,&nbsp;Akanksha Saxena,&nbsp;Manu Goyal","doi":"10.1007/s40200-022-01106-z","DOIUrl":"https://doi.org/10.1007/s40200-022-01106-z","url":null,"abstract":"<p><strong>Objectives: </strong>Diabetic Peripheral Neuropathy (DPN) is the commonest complication in individuals with type 2 diabetes mellitus affecting 50% of total diabetic population. The ankle mobility is seen to be significantly reduced along with alteration in plantar pressure distribution. Neural mobilization is a neoteric technique that is being used to treat various conditions of neural involvement. It is hypothesized that the application of neural mobilization will improve ankle mobility and plantar pressure distribution in individuals with DPN by restoring the mechanical and neurophysiological functions of the tibial and common peroneal nerves.</p><p><strong>Methods: </strong>A single group pre-post, quasi experimental, same subject design will be used. Participants with prior diagnosis of DPN will be selected according to eligibility criteria. The ankle ranges of motion (Both Active & Passive) and plantar pressure distribution at six foot regions will be taken as the outcome measures. All the participants will receive neural mobilization of tibial & common peroneal nerves (3 sets of 30 repetitions in 2 min with 1 min break in between) for 3 times/ week for 4 weeks. Outcome measurements will be taken at the baseline and after completion of the intervention.</p><p><strong>Conclusion: </strong>This study will be investigating the possible advantageous effects of neural mobilization in improving ankle joint ranges of motion and plantar pressure distribution in patients with DPN and will help the clinicians and researchers develop preventive measures to reduce the burden of diabetic ulcers.CTRI/2022/04/042187 [Registered on: 27/04/2022].</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672263/pdf/40200_2022_Article_1106.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9993678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of <i>Citrullus colocynthis</i> on glycemic factors and lipid profile in type II diabetic patients: a systematic review and meta-analysis.","authors":"Ali Jafarizadeh,&nbsp;Seyed Amin Raeisi,&nbsp;Nafiseh Ghassab-Abdollahi,&nbsp;Reza Yarani,&nbsp;Mostafa Araj-Khodaei,&nbsp;Mojgan Mirghafourvand","doi":"10.1007/s40200-022-01045-9","DOIUrl":"https://doi.org/10.1007/s40200-022-01045-9","url":null,"abstract":"<p><strong>Purpose: </strong>In this systematic review and meta-analysis, we investigated the effect and side effects of Citrullus colocynthis on glycemic factors and lipid profile in diabetic patients.</p><p><strong>Methods: </strong>We systematically searched English and Persian databases from inception till August 2021 using Medical Subject Headings (MeSH). Two authors independently extracted data and assessed the quality of studies. The standardized mean differences were pooled using fixed-effect models, and statistical heterogeneity was assessed using the I squared (I²) index.</p><p><strong>Results: </strong>Of the 321 articles searched in the databases, 136 related articles were screened, 14 relevant full-text articles were assessed for eligibility; finally, four articles were included in the study, three articles were entered into the meta-analysis. The results of the meta-analysis indicated that <i>Citrullus colocynthis</i> does not have a significant effect on fasting blood sugar (FBS), hemoglobin A1c (HBA1c), low-density lipoprotein (LDL), total cholesterol, and triglyceride indices but increases high-density lipoprotein (HDL) (Mean Difference: 5.76; 95% CI: 1.69 to 9.84; P = 0.006; I² = 0%).</p><p><strong>Conclusions: </strong>The meta-analysis results showed that <i>Citrullus colocynthis</i> has no significant effect on glycemic and metabolic indices of diabetes - except HDL. Due to the relatively low quality and the small number of included trials, conducting further large scale well-designed randomized clinical trials to determine the effect of <i>Citrullus colocynthis</i> on glycemic and metabolic indices seems essential.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-022-01045-9.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672250/pdf/40200_2022_Article_1045.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9994421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future treatment of Diabetes - Tyrosine Kinase inhibitors.","authors":"Aakash Kumar S, Snehal S Patel, Shreya Patel, Palak Parikh","doi":"10.1007/s40200-022-01164-3","DOIUrl":"10.1007/s40200-022-01164-3","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus (DM) is a group of metabolic disorders that have an increased risk of macro and micro-vascular complications due to lipid dysfunction. The present drug treatments for the management of DM either have numerous side effects or do not have long-lasting therapeutic effects. So it is essential to find a newer class of drug for DM treatment.</p><p><strong>Method: </strong>Broad information has been researched regarding Tyrosine kinase Inhibitors (TKIs) and their mechanism of action. They are proven for the management of various kinds of cancers. TKIs produce anti-hyperglycemic effects by acting on multiple targets such as c-Abl, Platelet-Derived Growth Factor Receptor (PDGFR), Vascular Endothelial Growth Factor Receptor (VEGFR), Epidermal Growth Factor Receptor (EGFR), and c-Kit.</p><p><strong>Result: </strong>This family of drugs blocks numerous tyrosine kinases by acting as a partial agonist of PPAR-γ receptors and results in an anti-diabetic effect by improving insulin sensitivity and glucose disposal rate.</p><p><strong>Conclusion: </strong>Therefore, it is said that TKI drugs will be great potential for the treatment of Diabetes. This review summarizes the possible targets of TKIs and TKIs being a potential drug class in the management of Diabetes mellitus.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9553581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha-lipoic acid administration affects psychological status and markers of inflammation and oxidative damage in patients with type 2 diabetes and coronary heart disease.","authors":"Vahidreza Ostadmohammadi,&nbsp;Fariba Raygan,&nbsp;Zatollah Asemi","doi":"10.1007/s40200-022-01031-1","DOIUrl":"https://doi.org/10.1007/s40200-022-01031-1","url":null,"abstract":"<p><strong>Background: </strong>This investigation was performed to assess the effects of alpha-lipoic acid (ALA) supplementation on psychological status and markers of inflammation and oxidative damage in patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD).</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled trial was performed in 60 patients with T2DM and CHD, aged 45-85 years. Patients were randomized into two groups to receive either 600 mg/day ALA (n = 30) or placebo (n = 30) for 12 weeks.</p><p><strong>Results: </strong>ALA supplementation significantly decreased Beck Depression Inventory index (BDI) (-5.1 ± 3.5 vs. -1.1 ± 4.8, P = 0.001) when compared with the placebo. ALA supplementation resulted also in a significant reduction of serum high sensitivity C-reactive protein (hs-CRP) (-0.8 ± 1.4 vs. +0.5 ± 0.6 mg/L, P < 0.001) and malondialdehyde (MDA) (-0.3 ± 0.2 vs. -0.1 ± 0.3 µmol/L, P = 0.003), and a significant increase in plasma total antioxidant capacity (TAC) levels (+ 26.8 ± 36.0 vs. -4.6 ± 43.4 mmol/L, P = 0.007) when compared with the placebo. ALA intake upregulated transforming growth factor beta (TGF-β) (P = 0.03) and downregulated gene expression of interleukin-1 (IL-1) (P = 0.001) in peripheral blood mononuclear cells of patients with T2DM and CHD as well.</p><p><strong>Conclusions: </strong>ALA supplementation for 12 weeks in patients with T2DM and CHD had beneficial effects on BDI, hs-CRP, TAC, MDA values, and gene expression of IL-1 and TGF-β.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-022-01031-1.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672217/pdf/40200_2022_Article_1031.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9573452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardioprotective effect of Hrudroga Chintamani Rasa in isoproterenol induced cardiotoxicity in male Sprague Dawley rats.","authors":"Ankit P Laddha,&nbsp;Mukesh B Chawda,&nbsp;Yogesh A Kulkarni","doi":"10.1007/s40200-022-01012-4","DOIUrl":"https://doi.org/10.1007/s40200-022-01012-4","url":null,"abstract":"<p><strong>Purpose: </strong>Ayurvedic system, a traditional medicinal system has mentioned a preparation Bruhat Vata Chintamani Rasa (Suvarnayukta) for management of heart diseases<i>.</i> Hrudroga Chintamani Rasa (HCR) is a formulation containing Bruhat Vata Chintamani Rasa and a few additional ingredients having beneficial effects in heart diseases. The present study was designed to investigate the cardioprotective activity of the Hrudroga Chintamani Rasa in isoproterenol (ISO)-induced myocardial infarction in rats.</p><p><strong>Methods: </strong>Male Sprague Dawley rats were treated with HCR at a dose of 56.16 and 112.32 mg/kg for 30 days. Animals received ISO (85 mg/kg. <i>s.c.</i>) on 28th and 29th day at an interval of 24 h.</p><p><strong>Result: </strong>Disease control animals treated with HCR at a dose of 56.16 mg/kg and 112.32 mg/kg to rats showed a significant reduction in elevated levels of aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine phosphokinase MB (CK-MB), and prevented loss of depleted antioxidant enzymes from the cardiac tissue. ISO-altered electrocardiogram pattern and haemodynamic parameters were also brought about to normal by treatment with HCR. HCR treatment also improved the levels of 5' adenosine monophosphate-activated protein kinase (AMPK) and Silent information regulator 1 (SIRT1) which have potent role in antioxidant defence mechanism. Histopathological findings also showed HCR treatment prevented cardiac tissue from damage.</p><p><strong>Conclusion: </strong>HCR treatment showed a significant cardioprotective effect in ISO-induced cardiotoxicity in rats probably because of the potent antioxidant activity.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-022-01012-4.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672163/pdf/40200_2022_Article_1012.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9133167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mineralocorticoid receptor blockade attenuates hyperandrogenic metabolic dysregulation in letrozole-induced PCOS rat model.","authors":"Efosa G Uhunmwangho,&nbsp;Adesola A Oniyide,&nbsp;Stephanie E Areloegbe,&nbsp;Olaniyi A Soetan,&nbsp;Christopher O Akintayo,&nbsp;Ayodeji Aturamu,&nbsp;Kehinde S Olaniyi","doi":"10.1007/s40200-022-01097-x","DOIUrl":"https://doi.org/10.1007/s40200-022-01097-x","url":null,"abstract":"<p><strong>Purpose: </strong>Polycystic ovarian syndrome (PCOS) is a metabolic syndrome associated with mineralocorticoid receptor (MR) activation, which causes infertility in women of reproductive age. Spironolactone (SPL) is a MR blocker with inconclusive effect in the treatment of PCOS. Therefore, the present study hypothesized that low dose SPL would ameliorate metabolic dysfunction associated with PCOS.</p><p><strong>Methods: </strong>Female Wistar rats (8-week-old) were divided into 3 groups namely: Control, SPL, Letrozole (LET)-treated and LET + SPL-treated groups. The control group was given vehicle (distilled water), SPL-treated group received 0.25 mg/kg, LET-treated group received 1 mg/kg of LET and LET + SPL-treated group received a combination of LET and SPL. The administrations were done by oral gavage for 21 days uninterruptedly. Biochemical parameters such as lipid profile, malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), γ-glutamyl transferase (GGT), lactate dehydrogenase (LDH), testosterone, 17-β estradiol and glutathione peroxidase (GPx) were determined with appropriate assay methods.</p><p><strong>Results: </strong>Letrozole-treated group had a significant increase in ovarian weight, plasma and ovarian triglycerides, MDA/TNF-α, GGT/LDH and plasma testosterone while it decreased plasma 17-β estradiol and plasma/ovarian high-density lipoproteins and GPx when compared with control group. In addition, histomorphological changes were observed in LET-treated group compared with control group. Nevertheless, administration of low dose SPL attenuated these perturbations.</p><p><strong>Conclusion: </strong>The present study therefore demonstrates that inhibition of mineralocorticoid receptor by low dose SPL ameliorates hyperandrogenic metabolic dysfunction in a rat model of PCOS. Therefore, low dose SPL is hereby suggested as a promising therapeutic agent in the management of PCOS.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672164/pdf/40200_2022_Article_1097.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9769608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of acetylcysteine, histidine, and their combination against diabetes vascular complications in type-2 diabetic rats via reducing NF-kβ pathway signaling.","authors":"Sina Mahdavifard,&nbsp;Manochehr Nakhjavani","doi":"10.1007/s40200-021-00967-0","DOIUrl":"https://doi.org/10.1007/s40200-021-00967-0","url":null,"abstract":"<p><strong>Purpose: </strong>The nuclear factor-kappa B (NF-κB) signaling participates in diabetes complications. Therefore, the reduction of NF-κB signaling may be a goal to prevent or improve them. Thus, we investigated the effects of acetylcysteine (AC), histidine (His), and their combination on the NF-κB expression and its different activators in type 2 diabetic rats.</p><p><strong>Methods: </strong>The survey was performed on 50 rats that were allotted equally into five groups composed of control, diabetic, diabetic treated with (AC, 0.06%), (His, 0.1%), and (AC & His) groups. Treated groups have received the treatments daily in drinking water for two months. Metabolic profile (glucose, insulin resistance indices, lipid profile, and cardiovascular indices) and renal dysfunction parameters (creatinine and urinary protein excretion) were measured. Plus, diverse glycation (early, intermediate, and end), oxidative stress (Oxidized LDL, Reduced glutathione), and inflammatory markers (interleukine-1β, myeloperoxidase, and NF-kβ expression) were determined.</p><p><strong>Results: </strong>Glucose, insulin resistance indices, cardiovascular indices, renal dysfunction parameters, different markers of glycation, oxidative stress, and inflammation as well as NF-κB expression, were the lowest in the (AC & His) treated diabetic rats. Besides, the cited parameter was lower in the Ac treated one than His treated (<i>p</i> > <i>0.001</i>).</p><p><strong>Conclusion: </strong>The combination of AC and His had the most protective effect against diabetes complications and advantageous effect on metabolism, β-cell activity, and insulin function due to the most reductive effect on the NF-κB pathway rather than More than any of the amino acids alone.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672179/pdf/40200_2021_Article_967.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10156539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}